Lv5
870 积分 2021-08-05 加入
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
6天前
已完结
First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group
1个月前
已完结
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
1个月前
已完结
Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study
1个月前
已完结
Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
3个月前
已完结
Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
3个月前
已完结
Encorafenib/binimetinib induced severe liver injury in a melanoma patient: Case report and review of literature
3个月前
已完结
Encorafenib overdose
3个月前
已完结
Demystifying BRAF Mutation Status in Colorectal Liver Metastases
5个月前
已完结
Prognostic factors of BRAF V600E colorectal cancer with liver metastases: a retrospective multicentric study
5个月前
已完结
皖公网安备34019202002308
